Accelerating Innovation at Leica Biosystems
Year-Over-Year Core Operating Margin Changes
DANAHER CORPORATION
Six-Month Period Ended July 3, 2020 Operating Profit Margins from Continuing Operations (GAAP)
First half of 2021 impact from operating profit margins of businesses that have been owned for less than one year or were disposed of during such
period and did not qualify as discontinued operations
First half of 2020 acquisition-related fair value adjustments to inventory and deferred revenue, transaction costs deemed significant and integration
preparation costs, net of first half of 2021 acquisition-related fair value adjustments to inventory and deferred revenue in each case related to the
acquisition of Cytiva
Year-over-year core operating profit margin changes for first half of 2021 (defined as all year-over-year operating profit margin changes other
than the changes identified in the line items above) (non-GAAP)
Six-Month Period Ended July 2, 2021 Operating Profit Margins from Continuing Operations (GAAP)
Total Company
16.00 %
1.55
2.50
8.35
Year Ended December 31, 2019 Operating Profit Margins from Continuing Operations (GAAP)
28.40 %
Total Company
18.30 %
1.25
Full year 2020 impact from operating profit margins of businesses that have been owned for less than one year or were disposed of during such
period and did not qualify as discontinued operations
Full year 2020 acquisition-related fair value adjustments to inventory and deferred revenue, transaction costs deemed significant and integration
preparation costs, net of full year 2019 transaction costs deemed significant and integration preparation costs, in each case related to the acquisition
of Cytiva
Third quarter 2020 impairment charges related to trade names in the Environmental & Applied Solutions segment
First quarter 2020 impairment charges related to a facility in the Diagnostics segment and a trade name and other intangible assets in the
Environmental & Applied Solutions segment
Year-over-year core operating profit margin changes for full year 2020 (defined as all year-over-year operating profit margin changes other
than the changes identified in the line items above) (non-GAAP)
Year Ended December 31, 2020 Operating Profit Margins from Continuing Operations (GAAP)
(2.15)
(0.05)
(0.05)
1.70
19.00 %
Year Ended December 31, 2018 Operating Profit Margins from Continuing Operations (GAAP)
Full year 2019 impact from operating profit margins of businesses that have been owned for less than one year or were disposed of during such
period and did not qualify as discontinued operations
Full year 2019 transaction costs deemed significant and integration preparation costs related to the anticipated acquisition of the GE Biopharma
business
Acquisition-related transaction costs deemed significant and fair value adjustments to inventory, in each case related to the acquisition of IDT and
incurred in the second quarter of 2018
Second quarter 2018 gain on resolution of acquisition-related matters
Year-over-year core operating profit margin changes for full year 2019 (defined as all year-over-year operating profit margin changes other
than the changes identified in the line items above) (non-GAAP)
Year Ended December 31, 2019 Operating Profit Margins from Continuing Operations (GAAP)
Total Company
17.90 %
(0.15)
(0.50)
0.10
(0.05)
1.00
18.30 %
7View entire presentation